NXGL Nexgel
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus · latest quarter in EDGAR: 2026-06-30
Nexgel (NXGL) is in ThetaGrade’s extended coverage. It does not have a House Rating; this is a fundamentals-only summary from SEC filings, compared with Health Care peers. Overall its fundamentals read Weak (Growth: below average; Profitability: average; Balance sheet: bottom quintile). 71% of the method weight is backed by data.
Data as of .
Growth
Below average| Revenue growth (TTM, YoY) | Below average |
| EPS growth (TTM, YoY) | data gap |
Profitability
Average| Operating margin (TTM) | Average |
| Free-cash-flow margin (TTM) | Average |
Balance sheet
Bottom quintile| Net debt / EBITDA | data gap |
| Current ratio | Bottom quintile |
| Interest coverage | Bottom quintile |
From the filings
- Operating loss (TTM)
- Revenue up year over year
- Net cash
- Free cash flow negative (TTM)
Next earnings
Estimated window 2026-05-13 to 2027-05-22 (rough estimate; estimated from SEC 8-K Item 2.02 filing history (not company-confirmed)). Back-test max error 187 days (> 7).
Why no House Rating
- price under $10
- market cap under $1B
House Ratings, Weekly Picks and the CSP screen cover the Tier 1 universe only. Methodology
Get rating changes in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium.
Educational summary from public SEC filings; not a House Rating and not financial advice. Sector: SIC 3841 (Surgical & Medical Instruments & Apparatus). Source: SEC EDGAR filings. Data as of 2026-10-21.